Ozempic Wrongful Death Lawsuits: What Patients Need to Know

What Is Happening With Ozempic Lawsuits Right Now

If you're taking Ozempic or thinking about starting a GLP-1 medication, you've probably seen alarming headlines about lawsuits. A wrongful death case has now been filed against Novo Nordisk, the company that makes Ozempic and Wegovy, marking a serious escalation in a wave of litigation that has been building for the past two years.

This is not a single isolated complaint. Hundreds of lawsuits have been consolidated in federal court, with plaintiffs alleging they experienced severe, undisclosed gastrointestinal injuries. The wrongful death filing signals that at least one family believes a GLP-1 medication directly contributed to a patient's death.

Understanding what these lawsuits actually claim, and what they don't, is critical before you make any decisions about your own treatment.

What the Lawsuits Actually Allege

The core legal argument in most GLP-1 lawsuits is not that semaglutide or tirzepatide are inherently dangerous drugs. The claims center on whether manufacturers adequately warned patients and physicians about known risks.

The Gastroparesis Concern

The most common allegation involves gastroparesis, a condition where the stomach empties far more slowly than normal. GLP-1 drugs work partly by slowing gastric emptying, which helps you feel full longer. Plaintiffs argue that in some patients this effect became severe and permanent, and that Novo Nordisk and Eli Lilly knew about this risk but did not make it clear enough in their official prescribing warnings.

Gastroparesis symptoms include persistent nausea, vomiting, bloating, and feeling full after eating very small amounts. Severe cases can lead to dangerous malnutrition and hospitalization.

Other Alleged Injuries

Beyond gastroparesis, lawsuits have also cited:

• Intestinal obstruction and ileus, a blockage that stops normal gut movement and can require emergency medical intervention
• Severe pancreatitis, or inflammation of the pancreas, which can be life-threatening if not recognized and treated promptly
• Aspiration during surgery, where stomach contents enter the lungs while under anesthesia because GLP-1 medications slowed gastric emptying beyond what standard fasting protocols account for
• Persistent cyclic vomiting syndrome, a pattern of severe, recurring vomiting episodes that did not resolve after dose adjustment or discontinuation

Not every plaintiff experienced the same injury, and the severity varied widely. What unites the cases is the allegation of inadequate warning.

How Serious Are These Risks? What the Research Says

It's important to separate headline-grabbing litigation from actual clinical evidence. GLP-1 medications have been extensively studied and have FDA approval for both type 2 diabetes management and chronic weight management.

Large clinical trials involving tens of thousands of patients showed significant cardiovascular and metabolic benefits. The SUSTAIN and STEP trial series for semaglutide, and the SURPASS trials for tirzepatide, demonstrated meaningful reductions in cardiovascular events, body weight, and blood sugar.

At the same time, gastrointestinal side effects are real and documented. The FDA has updated labeling for semaglutide products to include stronger warnings about ileus, and the agency continues to monitor postmarket safety data through its MedWatch reporting system.

A 2023 study published in JAMA examined GLP-1 users against comparable patients on other diabetes medications and found a statistically higher rate of pancreatitis, gastroparesis, and bowel obstruction among GLP-1 users. The absolute risk remained low, but the relative difference was meaningful enough to warrant attention.

The bottom line from the science: these are real but relatively uncommon risks. They are serious enough to deserve honest conversations between patients and their doctors.

What This Means If You Are Currently on a GLP-1 Drug

If you are currently taking Ozempic, Wegovy, Mounjaro, or any other GLP-1 medication, do not stop your medication abruptly without speaking to your doctor first. Stopping suddenly can cause blood sugar to spike if you are managing diabetes, and your weight loss progress may reverse.

What you should do right now:

1. Know Your Symptoms

Review the list of warning signs that require immediate medical attention:

• Severe or persistent abdominal pain
• Vomiting that lasts more than 24 hours or prevents you from keeping fluids down
• Feeling full after eating just a few bites for more than a week
• Yellowing of the skin or eyes, which is a possible sign of pancreatitis or liver involvement

These are not normal side effects to push through. They warrant a same-day call to your provider.

2. Tell Your Surgeon or Anesthesiologist

One serious and underreported risk involves surgical procedures. Because GLP-1 drugs slow stomach emptying, patients may have food or liquid in their stomachs even after following standard fasting instructions before surgery. Aspiration during anesthesia is a documented complication.

If you have any elective or emergency procedure scheduled, inform every member of your medical team that you are on a GLP-1 medication. American Society of Anesthesiologists guidelines now recommend holding GLP-1 medications for varying periods before procedures, depending on your dosing schedule.

3. Document Everything

Keep a record of any side effects you experience, including dates, severity, and how they affected your daily life. If you ever need to make a legal claim or file a report with the FDA, this documentation will matter.

What This Means If You Are Considering Starting a GLP-1 Drug

The existence of lawsuits should not automatically discourage you from exploring GLP-1 therapy. Millions of people have used these medications safely and achieved meaningful health improvements. But the litigation does underscore one thing: informed consent is non-negotiable.

Before you start any GLP-1 medication, you deserve clear answers to the following questions from your provider:

A provider who gives you vague answers or rushes through this conversation is a red flag. Choose care teams that treat informed consent as a priority, not a formality.

How to Choose a Provider With Your Safety in Mind

The growing litigation around GLP-1 drugs highlights how much provider quality matters. A physician who carefully screens patients, titrates doses conservatively, monitors for complications, and communicates clearly about risks is your best protection.

When comparing providers, look for:

• Medical supervision included, meaning not just an online prescription but actual follow-up appointments or check-ins with a licensed clinician
• Transparent risk communication, where the provider walks you through side effects before you sign up rather than burying the information in fine print
• Clear escalation protocols, including who you call if something goes wrong outside of business hours
• Personalized dosing plans, since cookie-cutter one-size-fits-all approaches to GLP-1 prescribing are not best practice

You can compare vetted telehealth and in-person providers at Best Providers, where options are evaluated based on clinical standards and patient experience, not just price.

How to Report a Side Effect

If you experience a serious side effect from any GLP-1 medication, you have the right and arguably the responsibility to report it. This data feeds directly into FDA safety reviews and can influence future label warnings.

You can file a report through the FDA's MedWatch program at fda.gov/safety/medwatch. Your doctor can also file on your behalf. Manufacturers are also required to report serious adverse events they become aware of.

Reporting does not start a lawsuit. It is simply a way to contribute to the broader safety picture for all patients using these medications.

The Legal Landscape: Where the Litigation Stands

As of mid-2025, GLP-1 lawsuits have been consolidated in the Eastern District of Pennsylvania as part of a multidistrict litigation (MDL) process. MDL is not a class action. Each plaintiff's case remains individual, but pretrial proceedings are coordinated to avoid duplicating discovery efforts across hundreds of cases.

The wrongful death lawsuit adds significant weight to the MDL because it raises the stakes from injury to death, which typically draws greater scrutiny of manufacturer conduct and internal communications.

Defendants (primarily Novo Nordisk and Eli Lilly) have denied that their warnings were inadequate and have pointed to FDA-approved labeling as evidence that disclosed risks appropriately. Courts will now weigh whether that labeling was sufficient given what the companies knew internally.

No settlements or verdicts have been publicly announced in the GLP-1 MDL as of the time of this writing. The litigation is expected to proceed for several years before any bellwether trials that could indicate how juries view the claims.

Cost Implications: Does Litigation Affect What You Pay?

You may wonder whether lawsuits will affect the cost or availability of GLP-1 medications. In the short term, probably not. These drugs remain among the best-selling pharmaceuticals in the world, and manufacturers are unlikely to pull them from the market.

However, litigation can sometimes accelerate label changes that affect prescribing patterns. If warnings become stronger, some insurers may tighten coverage criteria, which could affect your out-of-pocket costs.

Right now, cost remains one of the biggest barriers to GLP-1 access. Brand-name Ozempic can cost over $900 per month without insurance. If cost is a factor in your decision-making, explore GLP-1 Coupons for manufacturer savings programs and other legitimate discount options.

Compounded semaglutide was a popular lower-cost alternative, but FDA restrictions on compounding pharmacies tightened in 2025, narrowing those options. Make sure any compounded product you use comes from an FDA-registered 503B outsourcing facility with verifiable quality standards.